Leap Therapeutics Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer

Reuters10-20

Leap <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer

Leap Therapeutics Inc. announced the final results from Part B of the DeFianCe study, a Phase 2 clinical trial evaluating sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy for patients with microsatellite stable $(MSS)$ colorectal cancer who have received one prior systemic therapy for advanced disease. The final data were presented at the European Society for Medical Oncology (ESMO) Congress 2025. In the DKK1-high patient population, the objective response rate $(ORR)$ was 38.0% in the Sirexatamab Arm compared to 23.7% in the control arm. Leap Therapeutics plans to continue supporting the development of sirexatamab in DKK1-high colorectal cancer patients and to engage with regulatory authorities regarding its potential registrational path.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE00287) on October 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2576853490?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576853490","market":"nz","top_or_hot":-1,"title":"Leap Therapeutics Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Leap <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LPTX\">Leap Therapeutics Inc</a>. announced the final results from Part B of the DeFianCe study, a Phase 2 clinical trial evaluating sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy for patients with microsatellite stable <a href=\"https://laohu8.com/S/MSS\">$(MSS)$</a> colorectal cancer who have received one prior systemic therapy for advanced disease. The final data were presented at the European Society for Medical Oncology (ESMO) Congress 2025. In the DKK1-high patient population, the objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> was 38.0% in the Sirexatamab <a href=\"https://laohu8.com/S/ARM\">Arm</a> compared to 23.7% in the control arm. Leap Therapeutics plans to continue supporting the development of sirexatamab in DKK1-high colorectal cancer patients and to engage with regulatory authorities regarding its potential registrational path.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE00287) on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leap Therapeutics Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeap Therapeutics Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Leap <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LPTX\">Leap Therapeutics Inc</a>. announced the final results from Part B of the DeFianCe study, a Phase 2 clinical trial evaluating sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy for patients with microsatellite stable <a href=\"https://laohu8.com/S/MSS\">$(MSS)$</a> colorectal cancer who have received one prior systemic therapy for advanced disease. The final data were presented at the European Society for Medical Oncology (ESMO) Congress 2025. In the DKK1-high patient population, the objective response rate <a href=\"https://laohu8.com/S/ORR\">$(ORR)$</a> was 38.0% in the Sirexatamab <a href=\"https://laohu8.com/S/ARM\">Arm</a> compared to 23.7% in the control arm. Leap Therapeutics plans to continue supporting the development of sirexatamab in DKK1-high colorectal cancer patients and to engage with regulatory authorities regarding its potential registrational path.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE00287) on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL9Cctc3:1","article_id":"2576853490","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576853490","pubTimestamp":1760958063,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Leap Therapeutics Inc. announced the final results from Part B of the DeFianCe study, a Phase 2 clinical trial evaluating sirexatamab , an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy for patients with microsatellite stable  colorectal cancer who have received one prior systemic therapy for advanced disease. The final data were presented at the European Society for Medical Oncology  Congress 2025. In the DKK1-high patient population, the objective response rate  was 38.0% in the Sirexatamab Arm compared to 23.7% in the control arm. Leap Therapeutics plans to continue supporting the development of sirexatamab in DKK1-high colorectal cancer patients and to engage with regulatory authorities regarding its potential registrational path.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpose","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4505":"高瓴资本持仓","BK4563":"昨日强势股"},"translate_title":"Leap Therapeutics报告Sirexatamab可显着改善DKK1高结直肠癌的预后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LPTX":0.9},"content_text":"Leap Therapeutics Reports Sirexatamab Significantly Improves Outcomes in DKK1-High Colorectal Cancer\n    \n\nLeap Therapeutics Inc. announced the final results from Part B of the DeFianCe study, a Phase 2 clinical trial evaluating sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy for patients with microsatellite stable $(MSS)$ colorectal cancer who have received one prior systemic therapy for advanced disease. The final data were presented at the European Society for Medical Oncology (ESMO) Congress 2025. In the DKK1-high patient population, the objective response rate $(ORR)$ was 38.0% in the Sirexatamab Arm compared to 23.7% in the control arm. Leap Therapeutics plans to continue supporting the development of sirexatamab in DKK1-high colorectal cancer patients and to engage with regulatory authorities regarding its potential registrational path.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Leap Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE00287) on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2576853490","isCrawlerRequest":true}